Literature DB >> 16260804

Treatment with octreotide to suppress corticotropin secretion by a carcinoid tumour.

Eugenia B Tirovola1, James S Malpas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16260804      PMCID： PMC1276003          DOI： 10.1177/014107680509801116

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   18.000


× No keyword cloud information.
  5 in total

Review 1.  Somatostatin receptors in pituitary function, diagnosis and therapy.

Authors:  Leo J Hofland; Steven W J Lamberts
Journal:  Front Horm Res       Date:  2004       Impact factor: 2.606

2.  Failure of somatostatin analogue SMS 201-995 to control Cushing's syndrome due to ectopic release of ACTH from a bronchial carcinoid.

Authors:  L Burrell; C E Gray; J A Thomson
Journal:  Scott Med J       Date:  1989-10       Impact factor: 0.729

3.  Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors.

Authors:  Y Greenman; S Melmed
Journal:  J Clin Endocrinol Metab       Date:  1994-02       Impact factor: 5.958

4.  Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103.

Authors:  C Y Zhang; Y Yokogoshi; K Yoshimoto; Y Fujinaka; K Matsumoto; S Saito
Journal:  Biochem Biophys Res Commun       Date:  1995-05-25       Impact factor: 3.575

5.  Octreotide exerts different effects in vivo and in vitro in Cushing's disease.

Authors:  G K Stalla; S J Brockmeier; U Renner; C Newton; M Buchfelder; J Stalla; O A Müller
Journal:  Eur J Endocrinol       Date:  1994-02       Impact factor: 6.664
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.